Researchers created their new method to analyse chromosomes in 3D, revealing how misconfigurations play a role in cancer.
List view / Grid view
Researchers have measured the gene expression of healthy and cancerous single cells from breast tissue, creating an 'RNA atlas'.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
A range of imaging and computational techniques were used by researchers to discover the structure of the PH domain of PLEKHA7.
Researchers have developed a CAR T-cell engineering technique to ensure that only cancer cells are targeted, leaving healthy cells alone in solid tumours.
A team have shown that a tumour-suppressing and killing molecule delivered to the brain by stem cells has been successful in mice.
A proton therapy that targets cancer cells which are resistant to treatment has shown success, sparing surrounding healthy cells.
Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.
Drs Sam Cooper and Michael Briskin of Phenomic AI, discuss how artificial intelligence (AI) is enabling them to target multi-cellular interactions, such as those in the tumour stroma, for drug development.
Researchers show selectively activating androgen receptors could be an effective treatment for oestrogen receptor positive breast cancers.
Inhibiting the ACSS2 enzyme with a molecule called VY-3-135 caused a significant reduction in the growth of breast cancer tumours in vivo.
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
The Junior Editors of Drug Target Review, Victoria Rees and Hannah Balfour, discuss some of the most noteworthy news and announcements from this year.
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.